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ABSTRACT The objective of this study was to develop a population pharmacoki-
netic model and to determine a dosing regimen for caspofungin in critically ill pa-
tients. Nine blood samples were drawn per dosing occasion. Fifteen patients with
(suspected) invasive candidiasis had one dosing occasion and five had two dosing
occasions, measured on day 3 (1) of treatment. Pmetrics was used for population
pharmacokinetic modeling and probability of target attainment (PTA). A target 24-h
area under the concentration-time curve (AUC) value of 98 mg·h/liter was used as an
efficacy parameter. Secondarily, the AUC/MIC targets of 450, 865, and 1,185 were
used to calculate PTAs for Candida glabrata, C. albicans, and C. parapsilosis, respec-
tively. The final 2-compartment model included weight as a covariate on volume of
distribution (V). The mean V of the central compartment was 7.71 (standard devia-
tion [SD], 2.70) liters/kg of body weight, the mean elimination constant (Ke) was 0.09
(SD, 0.04) h1, the rate constant for the caspofungin distribution from the central to
the peripheral compartment was 0.44 (SD, 0.39) h1, and the rate constant for the
caspofungin distribution from the peripheral to the central compartment was 0.46
(SD, 0.35) h1. A loading dose of 2 mg/kg on the first day, followed by 1.25 mg/kg
as a maintenance dose, was chosen. With this dose, 98% of the patients were ex-
pected to reach the AUC target on the first day and 100% of the patients on the
third day. The registered caspofungin dose might not be suitable for critically ill pa-
tients who were all overweight (120 kg), over 80% of median weight (78 kg), and
around 25% of lower weight (50 kg). A weight-based dose regimen might be ap-
propriate for achieving adequate exposure of caspofungin in intensive care unit pa-
tients.
KEYWORDS caspofungin, pharmacodynamics, pharmacokinetics, population
pharmacokinetics, weight-based dosing
Caspofungin, an echinocandin antifungal drug, is used for the treatment of invasivecandidiasis (1–3). The European Society of Intensive Care Medicine (ESICM) and the
European Society of Microbiology and Infectious Disease (ESCMID) established a task
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force on the practical management of invasive candidiasis in critically ill patients (1).
The expert panel of these combined societies recommended echinocandins as the
primary therapy in critically ill patients with invasive candidiasis complicated by septic
shock and multiorgan failure (1). Other guidelines also recommend echinocandins as a
first-line treatment in critically ill patients (2, 4).
Previous studies have shown that caspofungin has both high pharmacokinetic
variability and considerable risk of low exposure in critically ill patients (5–7).
Currently, the caspofungin summary of product characteristics (SmPC) recommends
a maintenance dose of 70 mg daily for patients weighing over 80 kg and a reduced
dose for patients with lower body weight and for patients with moderate hepatic
impairment (8). It has been suggested that the caspofungin dose should be
escalated in critically ill patients to achieve adequate exposure (9, 10). Moreover,
some studies have shown that patients with hepatic impairment might not require
initial dose reduction, as after dosage alteration, lower exposure has been observed
(10, 11).
The first objective of this study was to develop and validate a population pharma-
cokinetic model for caspofungin. The secondary objective was to determine a dosage
regimen of caspofungin for critically ill patients.
RESULTS
Study population. This study included 20 intensive care unit (ICU) patients. For five
patients, the exposure was measured on two occasions (for two different dose regi-
mens) and for 15 patients on one occasion, resulting in 219 caspofungin concentra-
tions. Due to unforeseeable circumstances in the ICU care during the original study, six
samples could not be obtained; however, each of these six samples were on different
dosing occasions. The median age was 56 (minimum-maximum [min-max] range, 25 to
83) years, and the median weight was 78 (range, 48 to 139) kg. Two patients had severe
liver damage with a Child-Pugh score of C. The patient characteristics and pharmaco-
kinetic exposure analysis are described in Table 1.
Population pharmacokinetic model. During the modeling, one- and two-
compartment pharmacokinetic models were tested. After stepwise linear regression
analysis, albumin, sex, simplified acute physiology score (SAPS 3), bilirubin, ASAT
(aspartate transaminase), ALAT (alanine transaminase), hemodialysis, and age were
included as covariates in the model on different pharmacokinetic parameters. Overall,
24 models with different sets of covariates and error models were tested. All the tested
models are described in Table S1 in the supplemental material.
The final model was a two-compartment model with normalized population median
weight as a covariate on volume of distribution (V) using a gamma error model
TABLE 1 Patient characteristicsa
Characteristicb
Value (n  20; %
or min-max range)
Male (n) 11 (55)
Median age, yr 56 (25–83)
Median wt, kg 78 (48–139)
Coadministration of prednisolone-hydrocortisone 11 (55)
CVVH 8 (40)
Median SAPS 3 score 59 (31–104)
Median serum albumin (g/liter) 20 (14–28)
Median CRP (mg/liter) 124 (56–287)
Median serum creatinine (mg/liter) 83 (40–466)
Median ALAT (u/liter) 35.5 (7–598)
Median ASAT (u/liter) 39 (12–1776)
Median ALP (u/liter) 122 (56–460)
Median GGT (u/liter) 85.5 (16–941)
Median bilirubin (mmol/liter) 7.5 (3–376)
aThis table has been reproduced from reference 6.
bCVVH, continuous venovenous hemofiltration; CRP, C-reactive protein; ALP, alkaline phosphatase; GGT,
gamma-glutamyltransferase.
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(V  V0 · weight/78). The final run gamma value was 0.654, which confirms that no
significant noise was specified in the model (12). The mean V of the central compart-
ment was 7.71 (standard deviation [SD], 2.70) liters/kg, the mean elimination rate
constant (Ke) was 0.09 (SD, 0.04) h1, the rate constant for the caspofungin distribution
from the central to the peripheral compartment was 0.44 (SD, 0.39) h1, and the rate
constant for the caspofungin distribution from the peripheral to the central compart-
ment was 0.46 (SD, 0.35) h1. The population median weight was included as a
covariate in the final model, as it resulted in an improved goodness of fit and decreases
in Aikake information criterion (AIC) and 2 log likelihood values.
The final model population fit resulted in r of 0.75 and individual fit in r of 0.96. The
goodness-of-fit plots for population and individual caspofungin concentrations are
presented in Fig. 1. The final parameter estimates for the two-compartment population
model are presented in Table 2. The visual predictive check showed good performance
of the final model and did not reveal significant deviations or outliers. The visual
predictive check plot is presented in Fig. 2. The external validation with the digitized
data from Kurland et al. showed a fit of r  0.77 (Fig. 3), and data from Muilwijk et al.
showed a fit of r  0.83 (Fig. S1) (7, 13). The normalized prediction distribution error
(NPDE) plots are presented in Fig. S3.
Probability of target attainment (PTA). To evaluate the caspofungin registered
dose reported in the SmPC, fixed-dose regimens were simulated, where the population
weight was centered around three weight bands: 50 kg, 78 kg (population median), and
FIG 1 Goodness-of-fit plots for caspofungin. (A) Observed versus predicted population caspofungin concentrations. (B) Observed versus
predicted individual caspofungin concentrations.
TABLE 2 Final parameter estimates for the two-compartment caspofungin population
pharmacokinetic model
Pharmacokinetic parametera Mean SD Median CV%
Ke (h1) 0.09 0.04 0.08 42.38
V0 (liters/kg) 7.71 2.70 7.20 34.98
kcp (h1) 0.44 0.38 0.28 88.02
kpc (h1) 0.46 0.35 0.34 75.98
aKe, elimination rate constant; V0, volume of distribution; kcp, rate constant for the caspofungin distribution
from the central to the peripheral compartment; kpc, rate constant for the caspofungin distribution from the
peripheral to the central compartment.
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120 kg. The 70-mg dose resulted in 73% of 50-kg patients, 14% of 78-kg patients,
and 0% of 120-kg patients reaching the target area under the concentration-time
curve (AUC; 98 mg·h/liter) for the first day of therapy. Other fixed-dose regimens are
presented in Table 3.
For the weight-based dosing regimen, a dose of 2 mg/kg on the first day (loading
dose), followed by 1.25 mg/kg as a maintenance dose was the regimen that had the
highest success rate. With this dose, 98% of the patients are expected to reach the
target AUC (98 mg·h/liter) on the first day and 100% of the patients on the third day.
This dose regimen exceeded the upper-threshold AUC of 200 mg·h/liter for 21% and
15% of the patients on the first and third day, respectively. All the weight-based
dosages up to day 14 are presented in Table 4.
The MIC/AUC targets for C. glabrata, C. albicans, and C. parapsilosis were analyzed
with fixed and weight-based dose regimens. Using a MIC of 0.06 mg/liter from EUCAST
clinical breakpoints for fungi, all of the weight-based and fixed-dose regimens reached
the pharmacokinetic/pharmacodynamic (PK/PD) target at the third day for C. glabrata
and C. albicans (14). However, for C. parapsilosis, using MICs of 0.25 mg/liter and
1 mg/liter, our proposed weight-based regimens were not appropriate (15). The fixed-
dose regimens had an overall lower target attainment than weight-based regimens. All
the PTAs with the MIC range from 0.01 to 1.0 mg/liter are presented in Table 5. The C.
glabrata, C. albicans, and C. parapsilosis PTAs for the third day of therapy with different
weight-based dose regimens are presented in Fig. 4A to C.
FIG 2 Prediction-corrected visual predictive checks (pcVPCs) for the final two-compartment pharmacokinetic
model. The red line represents the median, and the blue dashed lines represent the 5th and 95th percentiles for
the observed data.
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We present a caspofungin population pharmacokinetic model developed using
Pmetrics. In Pmetrics, the nonparametric adaptive grid and parametric iterative two-
stage Bayesian approaches provide a robust pharmacokinetic model that is able to
capture subgroups and outliers in the population (16). Caspofungin population phar-
macokinetics were best described using a two-compartment pharmacokinetic model
using population median weight as a covariate on volume of distribution (V). This is in
agreement with a previous caspofungin model using nonlinear mixed-effects modeling
(NONMEM); however, in that model, plasma protein concentration was also included as
a covariate (9).
It has been shown in healthy adults that with increasing weight, both V and
clearance (CL) increase (17). In addition, a study conducted in critically ill patients
reported a V of 7.03 liters and CL of 0.54 liters/h, which is similar to our findings;
however, with a Ke of 0.09, our CL is approximately 0.7 liters (7). Other models have also
included weight as a covariate and obtained similar results (10, 18). Furthermore,
Nguyen et al. described that caspofungin exposure was influenced by albumin con-
centration and body weight (19). During our model development, albumin was also
tested as a covariate; however, this did not improve our final model, which might be
because albumin was not as frequently measured.
This study suggests that the registered caspofungin dose is not sufficient to achieve
PTA for all overweight individuals (120 kg) and over 80% of average-weight and
FIG 3 External validation with an independent cohort.
TABLE 3 Probability of target attainment using fixed caspofungin dosing regimens in different weight categories
Loading dose Maintenance dose
PTA (%) by weight category and AUC (mg·h/liter)
0–24 h 48–72 h
50 kg 78 kg 120 kg 50 kg 78 kg 120 kg
>98 >200 >98 >200 >98 >200 >98 >200 >98 >200 >98 >200
70 mg 50 mg 73 2 14 0 0 0 79 2 19 0 0 0
100 mg 70 mg 98 22 57 0 10 0 99 23 61 0 12 0
70 mg 73 2 14 0 0 0 98 15 53 0 11 0
100 mg 98 22 57 0 10 0 100 56 98 14 37 0
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around 25% of lower-weight (50 kg) critically ill patients. Our previous analysis
suggested using a weight-based dosage regimen of 1 mg/kg once daily; however,
probability of target attainment was not addressed (6, 20). The current dosing regimen
is based on a validated nonparametric population pharmacokinetic model and subse-
TABLE 4 Probability of target attainment using weight-based dosing regimens of caspofungin
Loading dose Maintenance dose
PTA (%) by AUC (mg·h/liter)
0–24 h 48–72 h 120–144 h 192–216 h 264–288 h 312–336 h
>98 >200 >98 >200 >98 >200 >98 >200 >98 >200 >98 >200
2 mg/kg 1 mg/kg 98 21 91 6 88 5 89 5 89 5 89 5
1.5 mg/kg 1.25 mg/kg 83 3 99 13 100 16 100 17 100 18 100 18
2 mg/kg 1.25 mg/kg 98 21 100 15 100 16 100 17 100 18 100 18
1 mg/kg 22 0 77 2 88 5 89 5 89 5 89 5
1.5 mg/kg 83 3 100 25 100 31 100 33 100 33 100 33
TABLE 5 Probability of target attainment for AUC/MIC targets of 450, 865, and 1,185 for
3rd day of caspofungin therapy (48 to 72 h)
Dose (mg/kg) and species
PTA (%) for MIC (mg/liter) ofa:
0.01 0.03 0.06 0.1 0.25 0.5 1.0
2–1 mg/kg
C. glabrata 100 100 100 100 62 2 0
C. albicans 100 100 100 99 3 0 0
C. parapsilosis 100 100 100 49 0 0 0
1.5–1.25 mg/kg
C. glabrata 100 100 100 100 95 7 0
C. albicans 100 100 100 100 9 0 0
C. parapsilosis 100 100 100 87 0 0 0
2–1.25 mg/kg
C. glabrata 100 100 100 100 97 9 0
C. albicans 100 100 100 100 11 0 0
C. parapsilosis 100 100 100 92 0 0 0
1 mg/kg
C. glabrata 100 100 100 100 44 0 0
C. albicans 100 100 100 97 1 0 0
C. parapsilosis 100 100 98 35 0 0 0
1.5 mg/kg
C. glabrata 100 100 100 100 99 16 0
C. albicans 100 100 100 100 19 0 0
C. parapsilosis 100 100 100 99 2 0 0
70 mg
C. glabrata 100 100 100 100 29 0 0
C. albicans 100 100 100 75 0 0 0
C. parapsilosis 100 100 98 26 0 0 0
70–50 mg
C. glabrata 100 100 100 99 8 0 0
C. albicans 100 100 98 26 0 0 0
C. parapsilosis 100 100 48 6 0 0 0
100 mg
C. glabrata 100 100 100 100 93 6 0
C. albicans 100 100 100 99 9 0 0
C. parapsilosis 100 100 100 84 0 0 0
100–70 mg
C. glabrata 100 100 100 100 31 0 0
C. albicans 100 100 100 82 0 0 0
C. parapsilosis 100 100 98 28 0 0 0
aAn AUC/MIC target of 450 was used for Candida glabrata, 865 for Candida albicans, and 1,185 for Candida
parapsilosis.
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quent Monte Carlo simulations. Using this method, we could calculate the PTAs for
different dosing regimens based on the developed population model. The most
appropriate dosage regimen reaching a 24-h steady-state AUC value of 98 mg·h/liter for
over 95% of simulated patients was a 2-mg/kg loading dose followed by a 1.25-mg/kg
daily dose. This approach might result in overall higher daily dosing than that with fixed
dosing; however, toxicity is not a major concern with caspofungin. A study with doses
of up to 200 mg daily for an extended period of time showed good tolerability was
observed, with no described dose-limiting toxicity (21). Additionally, a loading dose has
been shown to be necessary to achieve the AUC target on day 1 (22). We are looking
forward to the results of an ongoing prospective study investigating the impact of a
caspofungin loading dose of 140 mg (https://clinicaltrials.gov/ct2/show/NCT02413892).
We calculated the PTAs for AUC/MIC targets that have been proposed in a murine
study (24) and have also been implemented in multiple clinical studies (9, 10, 25). The
AUC/MIC target of a MIC of 0.06 mg/liter was reached for all weight-based dosing
regimens. However, as described previously, with the potentially increasing breakpoints
and higher MIC targets for C. parapsilosis, the optimal dose may be even higher than
that of our proposed weight-based dosing regimen to reach the proposed target (9).
The latest EUCAST clinical breakpoints for fungi suggest that isolates that are suscep-
tible to anidulafungin and micafungin should be considered susceptible to caspofun-
gin, as there is significant variability between laboratories in reported MIC ranges (14).
Martial et al. showed that, using the registered dosing regimen of caspofungin, the
AUC/MIC target of 865 is not reached and a 100-mg loading dose may be appropriate
for Candida species with a MIC of 0.125 mg/liter (10). Pérez-Pitarch et al. suggested
fixed dosing regimens up to 200 mg daily to cover Candida species with increasing MIC
(up to 0.25 mg/liter) (9). Furthermore, in most cases, at the start of the treatment, the
MIC of the Candida species is not known. To avoid a delay in appropriate antifungal
therapy, it is necessary to acquire adequate exposure to cover the susceptible Candida
species.
Our population is not representative for patients with liver failure, since only two of
the patients had severe liver failure (Child-Pugh score C). However, the population fit
did not show significant discrepancies for these 2 patients. Furthermore, liver function
markers aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-
glutamyl transpeptidase (GGT) were not included as covariates in the final model, as
these did not improve the population goodness of fit and other model parameters.
FIG 4 (A) Probability of target attainment on third day of therapy for AUC/MIC target of 450 for C. glabrata. (B) Probability of target attainment on third day
of therapy for AUC/MIC target of 865 for C. albicans. (C) Probability of target attainment on third day of therapy for AUC/MIC target of 1,185 for C. parapsilosis.
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Thus, these patients did not seem to form a different subgroup from the rest of the
population. Caspofungin clearance seems not to have changed in the patients with
Child-Pugh B and C, which explains why lower exposure was observed when doses
were reduced (10, 11).
This study has some limitations. First, we did not take plasma protein binding into
account while modeling, as we measured total caspofungin concentrations. As caspo-
fungin is highly protein bound (97%), the extent of protein binding can change in ICU
patients, and the measurement of unbound fractions may be useful; however, drug
assessment can be difficult, as small absolute errors translate into large relative errors
in highly protein-bound drugs (26, 27). Second, the PK/PD target for AUC is not well
established in clinical trials, and the currently used targets are based on murine models
only. These targets should be evaluated in prospective patient cohorts with clear
outcome measures. With respect to this, we suggest guiding therapy with therapeutic
drug monitoring to reach the optimal targets, as was performed in our initial study (6)
and other studies (5, 28).
In summary, we developed a two-compartment nonparametric population pharma-
cokinetic model and designed PTAs using AUC and AUC/MIC as targets. A weight-based
dose regimen of a 2-mg/kg loading dose and 1.25-mg/kg daily dose might be more
appropriate for achieving adequate exposure of caspofungin in ICU patients than the
standard fixed-dose regimen. This dosing regimen should be prospectively evaluated.
MATERIALS AND METHODS
Study population and sampling. This study included data from a prospective study in 20 adult
critically ill patients admitted to an ICU with suspected invasive candidiasis and treated with caspofungin
(6). For more details about the study population, see our previous publication (6).
All patients received a loading dose of 70 mg on the first day of treatment. The subsequent dose was
50 mg for patients weighing 80 kg, 70 mg for patients weighing 80 kg, and 35 mg and 50 mg,
respectively, for patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) (8). Caspofungin
was administered as a 1-h infusion.
As the steady state for caspofungin is reached on the second day after the loading dose, blood
sampling was performed on day 3 (range, 2 to 4) (22). If the dose was changed due to an area under the
concentration-time curve (AUC) value of 98 mg·h/liter, the sampling was repeated after 3 days. This
AUC exposure has been shown to be achieved in healthy volunteers after standard dosing, and 1-log kill
of C. albicans at an AUC of 98 mg·h/liter should be sufficient according to in vivo analysis (22, 24, 29). The
rationale for this target is described in detail in our previous publication (6). The sampling was performed
before the administration and 1, 2, 3, 4, 6, 8, 12, and 24 h after the start of the caspofungin infusion.
Caspofungin plasma concentrations were measured using a validated liquid chromatography-tandem
mass spectrometry assay (30).
Population pharmacokinetic modeling. The pharmacokinetic modeling, probability of target
attainment, and visual predictive checks were performed using the nonparametric adaptive grid program
(NPAG) in Pmetrics (version 1.5.2) for R (version 3.6.1) (Laboratory of Applied Pharmacokinetics and
Bioinformatics, Los Angeles, CA) (16).
The covariate selection was performed using the PMstep command of Pmetrics. Each covariate was
tested in a linear regression analysis on pharmacokinetic parameters to see if there was a significant
effect on AIC value (P  0.05). The covariates were retained in the model when the 2 log likelihood, AIC,
and Bayesian information criterion (BIC) values improved significantly and/or resulted in an improved
goodness-of-fit plot. The covariates, tested with a forward addition method, were weight, age, gender,
concomitant administration of prednisolone/hydrocortisone, dialysis, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), bilirubin, albumin, C-reactive
protein, leukocyte count, and simplified acute physiology score (SAPS 3).
Model diagnostics. The models were analyzed and compared using individual and population
observed versus predicted goodness-of-fit plots, AIC, BIC, and 2 log likelihood. The prediction error was
evaluated using bias (mean weighted prediction error) and imprecision (bias-adjusted mean weighted
squared prediction error) for both the individual and population models. During the population
modeling assay, error (standard deviation) and environmental noise were considered. For this, we used
error polynomials in the following equation: standard deviation  C0  C1 	 observed concentration.
The value 0.05 was used for C0 and 0.08 for C1. Gamma multiplicative and lambda additive error models
were tested to estimate residual error (12, 31).
The prediction- and variability-corrected visual predictive checks (pcVPCs) were done to evaluate the
performance of the final population pharmacokinetic model (32). The model was validated with two
external digitized data sets from caspofungin pharmacokinetic studies on critically ill patients (7, 13). The
data were digitized using WebPlotDigitizer (https://automeris.io/WebPlotDigitizer/), and a uniform dis-
tribution was used to sample random numbers from the weight range reported in the publication.
Probability of target attainment. The final population model was used for the Monte Carlo
simulations (n  1,000) to calculate the PTAs for different dosage regimens. For the primary PTA target,
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the 24-h steady-state AUC value of 98 mg·h/liter was used as an efficacy parameter and an AUC value of
200 mg·h/liter as an arbitrarily assigned upper threshold of twice the proposed efficacy target (22, 24, 29).
The PTAs were simulated for fixed and weight-based dosing for day 1, 3, 6, 9, 12, and 14 of therapy. Fixed
dosage regimens were a 70-mg loading dose on day 1, followed by a 50-mg daily dose; 100-mg loading
dose on day 1, followed by 70-mg daily dose; 70-mg daily dose; and 100-mg daily dose, with the
population weight averages of 50 kg, 78 kg (population median), and 120 kg. The weight-based dosing
regimens consisted of a 2-mg/kg loading dose followed by a 1-mg/kg daily dose; 2-mg/kg loading dose
followed by a 1.25-mg/kg daily dose; 1.5-mg/kg loading dose followed by a 1.25-mg/kg daily dose; no
loading dose and a 1-mg/kg daily dose; and no loading dose and a 1.5-mg/kg daily dose. A PTA of 90%
was considered an optimal target.
Second, the PK/PD target AUC/MIC were analyzed, as these have been used in previous pharmaco-
kinetic studies (9, 25, 33). An AUC/MIC target of 450 was used for Candida glabrata, 865 for Candida
albicans, and 1,185 for Candida parapsilosis. These AUC/MIC targets are based on a preclinical murine
study (24). PTAs were simulated for day 3 of therapy and for the MIC range of 0.01 to 1 mg/liter.
Data availability. Data are available upon request.
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